Filamentous fungi in the airway of patients with cystic fibrosis: Just spectators?

Viñado, Clara; Girón, Rosa; Ibáñez, Elisa; García-Ortega, Alberto; Pérez, Irene Lacruz; Polanco, Dinora; Pemán, Javier; Solé, Amparó

doi:10.1016/j.riam.2021.03.005

Cited by 6 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scedosporium species are human pathogenic moulds. They are the agents of eumycetoma [1][2][3][4][5], a chronic deep fungal infection of the skin and subcutaneous tissues, and are responsible for a broad spectrum of localised and life-threatening disseminated infections in immunocompetent and immunocompromised individuals [6][7][8][9][10] affecting numerous organs of the body (Figure 1A), including the bones and joints [11][12][13], the central nervous system [14][15][16][17], the eyes [18][19][20][21][22][23][24], the lungs [14,[25][26][27][28][29][30][31][32][33], the sinuses [34][35][36], and other body sites [37][38][39] of cystic fibrosis patients [8,28,[40][41][42], hematopoietic stem-cell and solid organ transplant recipients…”

Section: Introductionmentioning

confidence: 99%

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

Davies,

Thornton

2024

Preprint

View full text Add to dashboard Cite

Scedosporium species are human pathogenic fungi, responsible for chronic, localised, and life-threatening disseminated infections in both immunocompetent and immunocompromised individuals. Diagnosis of Scedosporium infections currently relies on non-specific CT, lengthy and insensitive culture from invasive biopsy, and time-consuming histopathology of tissue samples. At present, there are no rapid antigen tests that detect Scedosporium-specific biomarkers. Here we report the development of a rapid (30 min) and sensitive (pmol/L sensitivity) lateral-flow device (LFD) test, incorporating a Scedosporium-specific IgG1 monoclonal antibody (mAb), HG12, which binds to extracellular polysaccharide (EPS) antigens of between ~15 kDa and 250 kDa secreted during hyphal growth of the pathogens. The test is compatible with human serum, and allows the detection of the Scedosporium species most-frequently reported as agents of human disease (Scedosporium apiospermum, Scedosporium aurantiacum, and Scedosporium boydii), with limits of detection (LOD) of the EPS biomarkers in human serum of ~0.81 ng/mL (S. apiospermum), ~0.94 ng/mL (S. aurantiacum), and ~1.95 ng/mL (S. boydii). The Scedosporium-specific LFD (ScedLFD) test therefore provides a potential novel opportunity for the detection of infections caused by different Scedosporium species.

show abstract

Section: Introductionmentioning

confidence: 99%

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

Davies,

Thornton

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Scedosporium species are human pathogenic moulds. They are the agents of eumycetoma [1][2][3][4][5], a chronic deep fungal infection of the skin and subcutaneous tissues, and are responsible for a broad spectrum of localised and life-threatening disseminated infections in immunocompetent and immunocompromised individuals [6][7][8][9][10] affecting numerous organs of the body (Figure 1A), including the bones and joints [11][12][13], the central nervous system [14][15][16][17], the eyes [18][19][20][21][22][23][24], the lungs [14,[25][26][27][28][29][30][31][32][33], the sinuses [34][35][36], and other body sites [37][38][39] of cystic fibrosis patients [8,28,[40][41][42], haematopoietic stem cell and solid organ transplant recipients…”

Section: Introductionmentioning

confidence: 99%

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

Davies,

Thornton

2024

Diagnostics

View full text Add to dashboard Cite

Scedosporium species are human pathogenic fungi, responsible for chronic, localised, and life-threatening disseminated infections in both immunocompetent and immunocompromised individuals. The diagnosis of Scedosporium infections currently relies on non-specific CT, lengthy and insensitive culture from invasive biopsy, and the time-consuming histopathology of tissue samples. At present, there are no rapid antigen tests that detect Scedosporium-specific biomarkers. Here, we report the development of a rapid (30 min) and sensitive (pmol/L sensitivity) lateral-flow device (LFD) test, incorporating a Scedosporium-specific IgG1 monoclonal antibody (mAb), HG12, which binds to extracellular polysaccharide (EPS) antigens between ~15 kDa and 250 kDa secreted during the hyphal growth of the pathogens. The test is compatible with human serum and allows for the detection of the Scedosporium species most frequently reported as agents of human disease (Scedosporium apiospermum, Scedosporium aurantiacum, and Scedosporium boydii), with limits of detection (LODs) of the EPS biomarkers in human serum of ~0.81 ng/mL (S. apiospermum), ~0.94 ng/mL (S. aurantiacum), and ~1.95 ng/mL (S. boydii). The Scedosporium-specific LFD (ScedLFD) test therefore provides a potential novel opportunity for the detection of infections caused by different Scedosporium species.

show abstract